News

Study Identifies Key Pathway Behind Chemotherapy Resistance in Colon Cancer

Research Advances /

A study has identified a key molecular pathway that helps explain why colon cancer becomes resistant to chemotherapy. Researchers found that a protein called SALL4 is highly active in colon cancer and is linked to more advanced disease and poorer survival. SALL4 turns on another gene called CRIPTO, which is normally inactive in adults but […]

Study Identifies Key Pathway Behind Chemotherapy Resistance in Colon Cancer Read More »

Blood Test Detects Womb Cancer Recurrence Early with High Accuracy

Diagnostics /

Researchers have developed a new blood test called ECctDNA that can detect the return of womb (endometrial) cancer with high accuracy. The test works by finding tiny fragments of tumor DNA in the blood, offering a non-invasive alternative to pelvic exams, imaging, and biopsies. The test can deliver results within 48 hours and also identifies genetic

Blood Test Detects Womb Cancer Recurrence Early with High Accuracy Read More »

New Strategies Aim to Reduce Chemotherapy Risks in Extensive-Stage Small Cell Lung Cancer

Treatment /

Managing extensive-stage small cell lung cancer (ES-SCLC) involves not only treating the cancer aggressively but also preventing chemotherapy-induced myelosuppression, a dangerous drop in blood cell counts that can lead to infections like febrile neutropenia. One common strategy is the use of granulocyte colony-stimulating factor (G-CSF), which helps the body produce more neutrophils. It is often

New Strategies Aim to Reduce Chemotherapy Risks in Extensive-Stage Small Cell Lung Cancer Read More »

FDA Grants Full Approval to Tecartus, Reshaping Treatment Strategy for Mantle Cell Lymphoma

Treatment /

The U.S. Food and Drug Administration granted full approval to brexucabtagene autoleucel (Tecartus), a CAR T-cell therapy for relapsed or refractory mantle cell lymphoma (MCL), marking a major advance in treatment. According to Lore Gruenbaum of Blood Cancer United, the approval also raises new questions about how best to use this powerful therapy. The decision

FDA Grants Full Approval to Tecartus, Reshaping Treatment Strategy for Mantle Cell Lymphoma Read More »

China Accepts T-Pam Application, Advancing New Option for HER2-Positive Metastatic Breast Cancer

Drug Approvals /

China’s National Medical Products Administration has accepted a biologics license application for trastuzumab pamirtecan (T-Pam; DB-1303), moving it closer to becoming a new second-line treatment for HER2-positive metastatic breast cancer. The application is based on a Phase 3 trial comparing T-Pam with Kadcyla. The study showed that T-Pam significantly improved progression-free survival. It also demonstrated

China Accepts T-Pam Application, Advancing New Option for HER2-Positive Metastatic Breast Cancer Read More »

Orca-T and Orca-Q Show Promise for Safer Blood Cancer Transplants with Reduced GVHD

Targeted Therapy /

Orca-T and Orca-Q are emerging cell therapies that may improve outcomes in blood cancer transplants while reducing graft-versus-host disease (GVHD), according to Sagar S. Patel of Huntsman Cancer Institute. Orca-T is being tested in patients with acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS), particularly older or frail individuals who cannot tolerate intensive treatment. A

Orca-T and Orca-Q Show Promise for Safer Blood Cancer Transplants with Reduced GVHD Read More »

Sympathetic Nerves Found to Drive Pancreatic Cancer Growth, Study Reveals Sex Differences

Research Advances /

New research highlights how sympathetic nerves interact with cancer-associated fibroblasts (CAFs) to fuel pancreatic ductal adenocarcinoma (PDAC), one of the deadliest forms of cancer. The study shows that these nerves actively signal to CAFs, creating a tumor-supporting environment. Analysis of human PDAC samples revealed that high sympathetic nerve density is linked to faster disease progression

Sympathetic Nerves Found to Drive Pancreatic Cancer Growth, Study Reveals Sex Differences Read More »

FDA Approves Brexucabtagene Autoleucel for Relapsed Mantle Cell Lymphoma

Drug Approvals /

In April 2026, the FDA approved brexucabtagene autoleucel for patients with relapsed or refractory mantle cell lymphoma (MCL), offering the potential for long-term remissions, according to Lore Gruenbaum. The decision was based on results from the ZUMA-2 trial, which showed high response rates across patient groups. In earlier-line patients, the overall response rate was 91%

FDA Approves Brexucabtagene Autoleucel for Relapsed Mantle Cell Lymphoma Read More »

Personalized Cancer Vaccines Offer New Hope for Stable Melanoma Patients

Immunotherapy /

Melanoma treatment is moving toward personalized cancer vaccines designed for each patient’s unique genetic profile. While promising, their use is currently limited by how long they take to produce. Because these vaccines are custom-made, manufacturing takes about 6 to 9 weeks. This creates a critical waiting period, meaning the treatment works best for patients whose

Personalized Cancer Vaccines Offer New Hope for Stable Melanoma Patients Read More »

Gotistobart Shows Major Survival Benefit Over Chemotherapy in Squamous Lung Cancer Trial

Treatment /

Results from the Phase 3 PRESERVE-003 trial show that the immunotherapy gotistobart significantly outperforms standard chemotherapy in patients with previously treated advanced squamous non-small cell lung cancer. Compared to docetaxel, gotistobart reduced the risk of death by 54% and more than doubled the 12-month survival rate (63.1% vs. 30.3%). Median overall survival has not yet

Gotistobart Shows Major Survival Benefit Over Chemotherapy in Squamous Lung Cancer Trial Read More »